Microsatellite instability in the management of colorectal cancer

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 3, 2011, Pages 385-399

  Pino, Maria S ^a,b   Chung, Daniel C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

colorectal cancer; Lynch syndrome; microsatellite instability; mismatch repair genes; predictive marker; prognostic marker

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CYCLINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED;

3' UNTRANSLATED REGION; BAX GENE; CASP2 GENE; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; CRITERION VARIABLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; E2F4 GENE; ENDOMETRIUM CANCER; EPIGENETICS; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SILENCING; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEALTH CARE COST; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IGFIIR GENE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; MLH1 GENE; MLH3 GENE; MOLECULAR DIAGNOSIS; MSH2 GENE; MSH3 GENE; MSH6 GENE; ONCOGENE; OVARY CANCER; OVERALL SURVIVAL; PMS2 GENE; PRACTICE GUIDELINE; PROMOTER REGION; PROTEIN MOTIF; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE HOMOLOGY; SURVIVAL RATE; TGFBR2 GENE; URINALYSIS;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; MICROSATELLITE INSTABILITY; PATIENT SELECTION; PHENOTYPE; TREATMENT OUTCOME;

EID: 79958261864     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.25     Document Type: Review

References (112)

1. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet. Med. 11(1), 35-41 (2009).
2. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 138(6), 2073-2087 (2010).
3. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Bland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76(1), 1-18 (2006).
4. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29(4), 673-680 (2009). (Pubitemid 351494153)
5. Wang L, Cunningham JM, Winters JL et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 63(17), 5209-5212 (2003). (Pubitemid 37139829)
6. Svrcek M, El-Bchiri J, Chalastanis A et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J. Clin. Oncol. 25(27), 4231-4238 (2007). (Pubitemid 47548563)
7. Prolla TA, Pang Q, Alani E, Kolodner RD, Liskay RM. MLH1, PMS1, and MSH2 interactions during the initiation of DNA mismatch repair in yeast. Science 265(5175), 1091-1093 (1994). (Pubitemid 24293075)
8. Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J. Binding of mismatched microsatellite DNA sequences by the human MSH2 protein. Science 266(5189), 1403-1405 (1994).
9. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLa in human mismatch repair. Cell 126(2), 297-308 (2006). (Pubitemid 44092957)
10. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 62(9), 2447-2454 (2002). (Pubitemid 34462716)
11. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability. Science 268(5215), 1336-1338 (1995).
12. Rampino N, Yamamoto H, Ionov Y, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275(5302), 967-969 (1997). (Pubitemid 27087710)
13. Sammalkorpi H, Alhopuro P, Lehtonen R, et al. Background mutation frequency in microsatellite-unstable colorectal cancer. Cancer Res. 67(12), 5691-5698 (2007). (Pubitemid 46985001)
14. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58(22), 5248-5257 (1998). (Pubitemid 28521189)
15. Perucho M. Correspondence re: C.R. Boland, et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257, 1998. Cancer Res. 59(1), 249-256 (1999).
16. Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res. 61(11), 4545-4549 (2001). (Pubitemid 32685787)
17. Laiho P, Launonen V, Lahermo P, et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res. 62(4), 1166-1170 (2002). (Pubitemid 34160304)
18. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 123(6), 1804-1811 (2002). (Pubitemid 35408304)
19. Samowitz WS, Slattery ML, Potter JD, Leppert MF. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am. J. Pathol. 154(6), 1637-1641 (1999). (Pubitemid 29262844)
20. Pyatt R, Chadwick RB, Johnson CK, et al. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am. J. Pathol. 155(2), 349-353 (1999). (Pubitemid 29370385)
21. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96(4), 261-268 (2004). (Pubitemid 38256271)
22. Bacher JW, Flanagan LA, Smalley RL et al. Development of a fluorescent multiplex assay for detection of MSI-high tumors. Dis. Markers 20(4-5), 237-250 (2004). (Pubitemid 40164096)
23. Xicola RM, Llor X, Pons E, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J. Natl. Cancer Inst. 99(3), 244-252 (2007).
24. Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin. Cancer Res. 13(13), 3831-3839 (2007). (Pubitemid 47037588)
25. Hatch SB, Lightfoot HM, Garwacki CP et al. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin. Cancer Res. 11(6), 2180-2187 (2005). (Pubitemid 40490176)
26. Laghi L, Bianchi P, Malesci A. Differences and evolution of the methods for the assessment of microsatellite instability. Oncogene 27(49), 6313-6321 (2008).
27. Findeisen P, Kloor M, Merx S, et al. T25 repeat in the 3 untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res. 65(18), 8072-8078 (2005). (Pubitemid 41330567)
28. Bianchi F, Galizia E, Catalani R, et al. CAT25 is a mononucleotide marker to identify HNPCC patients. J. Mol. Diagn. 11(3), 248-252 (2009).
29. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J. Mol. Diagn. 10(4), 293-300 (2008). (Pubitemid 352019113)
30. De Jong AE, Van Puijenbroek M, Hendriks Y, et al. Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10(3), 972-980 (2004). (Pubitemid 38198898)
31. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet. Med. 11(1), 42-65 (2009).
32. Bessa X, Ballesté B, Andreu M, et al. A prospective, multicenter, population based study of BRAF mutational analysis for Lynch syndrome screening. Clin. Gastroenterol. Hepatol. 6(2), 206-214 (2008).
33. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin. Cancer Res. 10(1), 191-195 (2004). (Pubitemid 38114179)
34. Domingo E, Niessen RC, Oliveira C, et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24(24), 3995-3998 (2005). (Pubitemid 40896411)
35. Vasen HF, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on hereditary non-polyposis colorectal cancer (ICGHNPCC). Dis. Colon Rectum 34(5), 424-425 (1991).
36. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 116(6), 1453-1456 (1999). (Pubitemid 29258894)
37. Rodriguez-Bigas MA, Boland CR, Hamilton SR, et al. A National Cancer Institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda Guidelines. J. Natl Cancer Inst. 89(23), 1758-1762 (1997).
38. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J. Natl Cancer Inst. 96(4), 261-268 (2004). (Pubitemid 38256271)
39. Järvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118(5), 829-834 (2000). (Pubitemid 30243745)
40. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet. 44(6), 353-362 (2007). (Pubitemid 46953715)
41. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. Version 1.2010. National Comprehensive Cancer Network, Rockledge, PA, USA (2009).
42. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on families. Dis. Colon Rectum 45(12), 1588-1594 (2002). (Pubitemid 35471007)
43. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 94(6), 1708-1712 (2002). (Pubitemid 34241108)
44. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol. Oncol. 91(1), 74-80 (2003). (Pubitemid 37188596)
45. Renkonen-Sinisalo L, Btzow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int. J. Cancer 120(4), 821-824 (2007). (Pubitemid 46175402)
46. Goecke T, Schulmann K, Engel C, et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J. Clin. Oncol. 24(26), 4285-4292 (2006). (Pubitemid 46630786)
47. Vasen HF, Möslein G, Alonso A, et al. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Fam. Cancer 9(2), 109-115 (2010).
48. Lindor NM, Rabe K, Petersen GM, et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16), 1979-1985 (2005). (Pubitemid 40570891)
49. Llor X, Pons E, Xicola RM, et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin. Cancer Res. 11(20), 7304-7310 (2005). (Pubitemid 41507688)
50. Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354, 2751-2763 (2006). (Pubitemid 43974193)
51. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N. Engl. J. Med. 352(18), 1851-1860 (2005).
52. Casey G, Lindor NM, Papadopoulos N et al. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer. JAMA 293(7), 799-809 (2005). (Pubitemid 40250363)
53. Pino MS, Mino-Kenudson M, Wildemore BM, et al. Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas. J. Mol. Diagn. 11(3), 238-247 (2009).
54. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet. Med. 12(2), 93-104 (2010).
55. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296(12), 1479-1487 (2006). (Pubitemid 44465512)
56. Balmana J, Stockwell DH, Steyerberg EW et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296(12), 1469-1478 (2006). (Pubitemid 44465511)
57. Barnetson RA, Tenesa A, Farrington SM et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354(26), 2751-2763 (2006). (Pubitemid 43974193)
58. Pouchet CJ, Wong N, Chong G, et al. A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. Ann. Oncol. 20(4), 681-688 (2009).
59. Boland CR. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J. Clin. Oncol. 25(7), 754-756 (2007). (Pubitemid 350002872)
60. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342(2), 69-77 (2000). (Pubitemid 30036597)
61. Benatti P, Gafà R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 11(23), 8332-8340 (2005). (Pubitemid 41746945)
62. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005). (Pubitemid 46224239)
63. Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100(2), 266-273 (2009).
64. Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26(16), 2690-2698 (2008).
65. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer. 45(3), 365-373 (2009).
66. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25(7), 767-772 (2007). (Pubitemid 350002875)
67. Klump B, Nehls O, Okech T, et al. Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int. J. Colorectal Dis. 19(1), 23-42 (2004). (Pubitemid 38088282)
68. Schwitalle Y, Kloor M, Eiermann S, et al. Immune response against frameshiftinduced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134(4), 988-997 (2008). (Pubitemid 351459601)
69. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 15(20), 6412-6420 (2009).
70. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 222(4), 350-366 (2010).
71. Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 138(4), 1406-1417 (2010).
72. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1), 123-131 (1999). (Pubitemid 29297628)
73. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217), 1745-1750 (2000). (Pubitemid 30265078)
74. Hemminki A, Mecklin JP, Järvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119(4), 921-928 (2000).
75. Liang JT, Huang KC, Lai HS, et al. High-frequency microsatellite instability predict better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int. J. Cancer. 101(6), 519-525 (2002).
76. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3) 247-257 (2003). (Pubitemid 36859476)
77. Storojeva I, Boulay JL, Heinimann K, et al. Prognostic and predictive relevance of microsatellite instability in colorectal cancer. Oncol. Rep. 14(1), 241-249 (2005).
78. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55(6), 848-855 (2006). (Pubitemid 43764557)
79. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol. 24(15), 2359-2367 (2006). (Pubitemid 46630668)
80. Lamberti C, Lundin S, Bogdanow M, et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int. J. Colorectal Dis. 22(2), 145-152 (2007). (Pubitemid 44964017)
81. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer. 45(10), 1890-1896 (2009).
82. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27(11), 1814-1821 (2009).
83. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracilbased adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219-3226 (2010).
84. Koi M, Umar A, Chauhan DP, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N-nitro-Nnitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54(16), 4308-4312 (1994).
85. Hawn MT, Umar A, Carethers JM, et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 55(17), 3721-3725 (1995).
86. Carethers JM, Hawn MT, Chauhan DP et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N-nitro- Nnitrosoguanidine. J. Clin. Invest. 98(1), 199-206 (1996). (Pubitemid 26243837)
87. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56(21), 4881-4886 (1996). (Pubitemid 26374423)
88. Aebi S, Fink D, Gordon R, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res. 3(10), 1763-1767 (1997). (Pubitemid 27444715)
89. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 61(13), 5193-5201 (2001). (Pubitemid 32681553)
90. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem. 280(7), 5516-5526 (2005). (Pubitemid 40280029)
91. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer. 106(1), 66-73 (2003). (Pubitemid 36750389)
92. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS a recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 127(6), 1678-1684 (2004). (Pubitemid 39575846)
93. Vilar E, Scaltriti M, Balmaña J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer. 99(10), 1607-1612 (2008).
94. Magrini R, Bhonde MR, Hanski ML, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 101(1), 23-31 (2002). (Pubitemid 34832993)
95. Jacob S, Aguado M, Fallik D, Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 61(17), 6555-6562 (2001). (Pubitemid 32783264)
96. Rodriguez R, Hansen LT, Phear G et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin. Cancer. Res. 14(17), 5476-5483 (2008).
97. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J. Clin. Oncol. 25(23), 3456-3461 (2007). (Pubitemid 47310883)
98. Van Cutsem E, Labianca R, Bodoky G et al. Randomized Phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27(19), 3117-3125 (2009).
99. Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 63(18), 5738-5744 (2003). (Pubitemid 37187470)
100. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract 4001]. J. Clin. Oncol. 27(Suppl. 15), S169 (2009).
101. Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), 2020-2029 (2007).
102. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19), 3109-3116 (2009).
103. des Guetz G, Mariani P, Cucherousset J et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 27(4C), 2715-2719 (2007). (Pubitemid 47227987)
104. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother. Pharmacol. 66(4), 659-667 (2010).
105. Kim ST, Lee J, Park SH, et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med. Oncol. 27(4), 1277-1285 (2010).
106. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol. 21(4), 772-780 (2010).
107. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5(9), 689-698 (2005). (Pubitemid 41486362)
108. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26(22), 3785-3790 (2008).
109. Miquel C, Jacob S, Grandjouan S, et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 26(40), 5919-5926 (2007).
110. Vilar Sanchez E, Chow A, Raskin L, Iniesta MD, Mukherjee B, Grube SB. Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J. Clin. Oncol. 27(15 Suppl.) Abstract 11028 (2009).
111. Vilar E, Mukherjee B, Kuick R, et al. Gene expression patterns in mismatch repair-deficient colorectal cancers highlights the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT- mammalian target of rapamycin pathway. Clin. Cancer Res. 15(8), 2829-2839 (2009).
112. Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11(6), 498-512 (2007). (Pubitemid 46856907)